Case of Epstein‐Barr virus‐associated transformation of mantle cell lymphoma

Terasawa, Teruhiko; Ohashi, Haruhiko; Utsumi, Makoto; Tsushita, Keitaro; Kinoshita, Tomohiro; Nakamura, Shigeo; Saito, Hidehiko

doi:10.1002/ajh.10343

Cited by 12 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rearrangement of MYC and a mutation in NOTCH2 were believed to have induced the immunophenotypic transformation of MCL cells in this patient (19). It has also been reported that EBV can drive the conversion of MCL to DLBCL (20). The concept of a double-hit lymphoma was first defined in 2011 as any lymphoma with a chromosomal breakpoint affecting the MYC/8q24 locus in combination with another recurrent breakpoint, usually t (14;18) (q32;q21) involving BCL2 but occasionally t(11;14) (q13;q32) involving CCND1 (21).…”

Section: Discussionmentioning

confidence: 71%

Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report

He¹,

Mao²,

Cheng³

et al. 2022

Front. Hematol.

View full text Add to dashboard Cite

Relapsed/refractory (R/R) mantle cell lymphoma (MCL) with primary drug resistance to Bruton tyrosine kinase inhibitor and mutated TP53 responds poorly to conventional treatments. Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the most effective treatments for R/R B cell lymphoma. However, no reports of CD5 CAR T cell treatment for MCL have been reported. In this paper, we report a R/R MCL patient with primary drug resistance to BTK inhibitors and TP53 mutation enrolled in a human CD5 CAR T cell trial. Remission of the primary disease was observed half a month after CAR T cell infusion. However, ascites was observed 2 weeks later. Flow cytometry suggested disease progression and immunophenotypic transformation. CD5 in CAR T cells turned negative and the expression of CD38 was enhanced. The patient was treated with a combination of daratumumab and Gemox (gemcitabine + oxaliplatin), abdominal distension and pain were markedly reduced, and ascites disappeared. We report the first case of human CD5 CAR T cell treatment for a patient with R/R MCL, providing insight on treatment strategies for such patients.

show abstract

Section: Discussionmentioning

confidence: 71%

Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report

He¹,

Mao²,

Cheng³

et al. 2022

Front. Hematol.

View full text Add to dashboard Cite

show abstract

“…In this report, the patient developed DLBCL approximately 9 years after a diagnosis of MCL was made. The tumor cells appeared to lack expression of both CD5 and cyclin D1 suggesting that they were not clonally related to the underlying MCL [12]. Unfortunately we were unable to definitively assess clonal relationship in our cases by immunoglobulin sequencing as it was not possible to extract DNA of sufficient quality from the paraffin embedded tissue blocks.…”

mentioning

confidence: 68%

Development of EBV-associated diffuse large B-cell lymphoma in Waldenström macroglobulinemia and mantle cell lymphoma

Varghese

Sayala

Evans

et al. 2008

Leukemia & Lymphoma

View full text Add to dashboard Cite

“…In 2003, Terasawa et al. ( 10 ) reported a case of MCL, which relapsed 8 years later and transformed into invasive diffuse large B-cell lymphoma (DLBCL); EBV was detected in the DLBCL. Southern hybridization with an EBV terminal repeat probe showed a clear monoclonal pattern in DLBCL specimens.…”

Section: Discussionmentioning

confidence: 99%

“…At present, there are few studies on EBV-associated mantle cell lymphoma (MCL), and most of them are case reports (9)(10)(11)(12)(13)(14)(15)(16). These studies have established the connection between EBV and MCL.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathologic study of mantle cell lymphoma with epstein-barr virus infection: A case series and literature review

Zhou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMantle cell lymphoma (MCL) with Epstein–Barr virus (EBV) infection is rarely reported. The objective of this study was to analyze the prevalence and clinicopathological features of MCL with EBV infection in the largest series thus far.MethodsAfter screening 138 cases of MCL, we identified eight cases of MCL with EBV infection.ResultsMost of them (7/8) had non-neoplastic bystander cells with positivity for EBV and no expression of latent membrane protein 1 (LMP1) and EBV nuclear antigen 2 (EBNA2). The cases of MCL with EBER positivity did not have abnormal immune function or other lymphomas. Moreover, their histopathological morphology was indicative of classical MCL. Cases of MCL with EBER positivity exhibited statistically significant differences in lactate dehydrogenase, anemia status, and MCL international prognostic index grouping (P=0.008, P=0.02, P=0.001, and P=0.011, respectively). The differences between the two groups in age, sex ratio, clinical manifestations, and immunohistochemical phenotypes were not statistically significant.ConclusionsThe incidence of MCL with EBV infection was low (5.8%). Clinicopathologically, cases of MCL with EBER positivity were similar to their EBV-negative counterparts. Our findings revealed that most cells infected by EBV in MCL are background cells rather than tumor cells. This is inconsistent with data from previous studies, indicating that tumor cells in MCL may not be prone to EBV infection.

show abstract

Case of Epstein‐Barr virus‐associated transformation of mantle cell lymphoma

Cited by 12 publications

References 21 publications

Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report

Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report

Development of EBV-associated diffuse large B-cell lymphoma in Waldenström macroglobulinemia and mantle cell lymphoma

Clinicopathologic study of mantle cell lymphoma with epstein-barr virus infection: A case series and literature review

Contact Info

Product

Resources

About